Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Foreword

Article

Author(s): Karen R Lui Added: 3 years ago
TodayÔÇÖs medical professional hardly goes a day without reading about or discussing the topic of 'disease managementÔÇÖ. While the term 'secondary preventionÔÇÖ has been around much longer, the newly emerging term refers to managing the chronic illness of large populations. The implications of this rapidly growing strategy are great for the future delivery of secondary prevention services to… View more
Author(s): Marjorie L King , Randal J Thomas Added: 3 years ago
In spite of growing scientific evidence of the benefits of cardiac rehabilitation and secondary prevention programs, these programs remain underutilized, with fewer than 30% of eligible patients participating. This occurs despite evidence that participation in cardiac rehabilitation is associated with a mortality benefit of approximately 20–25%.1 Although barriers to participation are… View more
Author(s): Edwin E Ferguson Added: 3 years ago
Cardiac rehabilitation (CR) refers to coordinated multifaceted interventions designed to optimize a cardiac patient's physical, social, and psychological functioning, with the additional goals of stabilizing, slowing, or even reversing the progression of the underlying atherosclerotic processes, thereby reducing morbidity and mortality. CR is a comprehensive secondary prevention program that… View more
Foreword

Article

Author(s): Gregory J Dehmer Added: 3 years ago
Before 1900, infectious diseases and malnutrition were the most common causes of death. However, as robust economies developed, the common causes of death in these economies shifted to cardiovascular diseases and cancer. This shift was largely due to improved nutrition and public health measures. At the same time, easier access to less expensive foods with a higher fat content has led to an… View more
Author(s): Edwin E Ferguson Added: 3 years ago
Cardiac rehabilitation (CR) refers to coordinated multifaceted interventions designed to optimize a cardiac patient's physical, social, and psychological functioning, with the additional goals of stabilizing, slowing, or even reversing the progression of the underlying atherosclerotic processes, thereby reducing morbidity and mortality.1CR is a comprehensive secondary prevention program that… View more
Foreword

Article

Author(s): Marjorie L King Added: 3 years ago
Despite significant advances in the prevention and treatment of coronary artery disease over the past decade, there has not been a corresponding decrease in the prevalence of cardiovascular risk factors. Obesity is a growing epidemic and cigarette use continues to increase, especially in developing countries. As a practicing cardiologist in the metropolitan New York area, I often note how… View more
Author(s): Randall S Stafford , Veronica Monti , Jun Ma Added: 3 years ago
Cardiovascular disease (CVD), including myocardial infarction and stroke, is the leading cause of morbidity and mortality in the US. A broad array of randomized trials have demonstrated the benefits of low doses of aspirin (75-325mg)1,2 for both the primary3-7 and secondary8-11 prevention of CVD. Most trials demonstrate a 15-40% reduction in cardiovascular events with chronic aspirin use.Aspirin… View more
Author(s): Randall S Stafford , Veronica Monti , Jun Ma Added: 3 years ago
Cardiovascular disease (CVD), including myocardial infarction and stroke, is the leading cause of morbidity and mortality in the US. A broad array of randomized trials have demonstrated the benefits of low doses of aspirin (75-325mg)1,2 for both the primary3-7 and secondary8-11 prevention of CVD. Most trials demonstrate a 15-40% reduction in cardiovascular events with chronic aspirin use.Aspirin… View more
Author(s): Charles H Hennekens , Danielle Hollar Added: 3 years ago
While the proximate cause of virtually all acute cardiovascular disease (CVD) syndromes is thrombosis, the principal underlying cause is atherosclerosis.1 With respect to aspirin, in basic research this drug irrepressibly acetylates the active site of cyclo-oxygenase in platelets which inhibits thromboxane A2, a powerful promoter of aggregation.2 In randomized trials of secondary prevention and… View more
Author(s): Charles H Hennekens , Danielle Hollar , Arthur S Agatston Added: 3 years ago
While the proximate cause of virtually all acute cardiovascular disease (CVD) syndromes is thrombosis, the principal underlying cause is atherosclerosis. With respect to aspirin, in basic research this drug irrepressibly acetylates the active site of cyclo-oxygenase in platelets which inhibits thromboxane A2, a powerful promoter of aggregation. In randomized trials of secondary prevention and… View more